Clinical Trial

Precision Supplemental Imaging in Women With Dense Breasts

Study acronym: PSID
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2029-06-30 -> 2029-08-31 2026-07-16
minor Completion pushed: 2029-06-30 -> 2029-08-31 2026-07-16
notable Primary completion pushed: 2029-03-31 -> 2029-06-30 2026-05-21
minor Completion pushed: 2029-03-31 -> 2029-06-30 2026-05-21
Trial Details
NCT Number NCT07277738
Lead Sponsor Washington University School of Medicine
Conditions Breast Cancer, Cancer of the Breast
Enrollment 78 participants
Start Date 2026-08-31
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15